(NASDAQ: MBRX) Moleculin Biotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.
Moleculin Biotech's earnings in 2025 is -$21,763,000.On average, 2 Wall Street analysts forecast MBRX's earnings for 2025 to be -$25,690,906, with the lowest MBRX earnings forecast at -$28,280,998, and the highest MBRX earnings forecast at -$23,100,815. On average, 1 Wall Street analyst forecast MBRX's earnings for 2026 to be -$25,200,889, with the lowest MBRX earnings forecast at -$25,200,889, and the highest MBRX earnings forecast at -$25,200,889.
In 2027, MBRX is forecast to generate -$24,220,855 in earnings, with the lowest earnings forecast at -$24,220,855 and the highest earnings forecast at -$24,220,855.